English
This Project is not specific to Greece. For more details, please visit OpenAIRE Explore.
Link with research outputs.
Please log in first and try again.
Completed
Translating potent SARS-Cov-2 neutralising nanobodies from the lab to the clinic
FunderUK Research and Innovation
Funder Contribution £200,392.00
Duration01 Dec 2020 - 30 May 2021
Funded underCOVID
Project codeMR/V03958X/1
Open Access mandatePublications: NoResearch data: No
Identifiers
Project timeline100%
Description
There is currently no cure for Covid-19. However, treatment with antibodies that block SARS-CoV2 from infecting cells may halt or ameliorate disease. We have produced very potent mini-antibodies or nanobodies that neutralise the virus in "test-tube" experiments with 100 % efficiency. The small size and stability of the nanobodies make them candidates for direct delivery into the lungs using a nebuliser device with the idea of rapidly reducing infection in the airways. The highly neutralising SARS-Cov2 nanobodies that we have generated are ready for animal tests. Successful demonstration of activity in animals will be the key step to developing this novel way of treating Covid19 with antibodies.
Partners (2)
Start a new DMP in Loading
There is currently no cure for Covid-19. However, treatment with antibodies that block SARS-CoV2 from infecting cells may halt or ameliorate disease. We have produced very potent mini-antibodies or nanobodies that neutralise the virus in "test-tube" experiments with 100 % efficiency. The small size and stability of the nanobodies make them candidates for direct delivery into the lungs using a nebuliser device with the idea of rapidly reducing infection in the airways. The highly neutralising SARS-Cov2 nanobodies that we have generated are ready for animal tests. Successful demonstration of activity in animals will be the key step to developing this novel way of treating Covid19 with antibodies.
